HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,009-1,020 of 4,505
Drug study icon
CompletedNCT00490516

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

What is this study about?

Researchers compared ACP-104 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Anaheim
SchizophreniaMedication studyAges 18–60
Countries
United States
Sponsor
ACADIA Pharmaceuticals Inc.
Drug study icon
TerminatedNCT01908192

Adaptive Phase II Study Safety & Efficacy of NaBen®

What is this study about?

This study evaluates the safety and effectiveness of NaBen® for people with schizophrenia.

This study ended early.

Multiple locations, including Dothan
SchizophreniaMedication studyAges 12–17
Countries
United States, Taiwan
Sponsor
SyneuRx International (Taiwan) Corp
Drug study icon
CompletedNCT03788759

Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia

Official study title

Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia: A Randomized, Double-blind, Placebo-controlled Trial

This study has finished and is no longer accepting participants.

In Fortaleza
SchizophreniaMedication studyAges 18–60
Countries
Brazil
Sponsor
Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Drug study icon
CompletedNCT00992407

Long Acting Injectable Risperidone and Oral Risperidone for schizophrenia

Official study title

A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder

This study has finished and is no longer accepting participants.

In Ansan
SchizophreniaMedication studyAges 18–55
Countries
South Korea
Sponsor
Janssen Korea, Ltd., Korea
Drug study icon
CompletedNCT00460512

Safety study of Flexibly Dosed Paliperidone Extended Release (ER) in schizophrenia

What is this study about?

Researchers studied Paliperidone ER to find out how it affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Antwerp
SchizophreniaMedication studyAges 18+
Countries
France, United Kingdom, Switzerland, + 19 others
Sponsor
Janssen-Cilag International NV
Device study icon
CompletedNCT06486948

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

Official study title

A Multicenter, Exploratory, Randomized, Double-Arm, 8-week Study to Evaluate the Feasibility and Acceptability of an Abbreviated Treatment with CT-156 in People with Schizophrenia

This study has finished and is no longer accepting participants.

In New York
SchizophreniaDevice studyAges 18+
Countries
United States
Sponsor
Click Therapeutics, Inc.
Device study icon
CompletedNCT06067984

Second Course of a Digital Therapeutic for schizophrenia

Official study title

A Single-Arm, Open Label, 16-week Extension Study to Evaluate the Efficacy and Safety of a Second Course of a Digital Therapeutic as an Adjunct to Standard of Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia

This study has finished and is no longer accepting participants.

In New York
SchizophreniaDevice studyAges 18+
Countries
United States
Sponsor
Click Therapeutics, Inc.
Drug study icon
CompletedNCT02970929

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

What is this study about?

Researchers studied SEP-363856, tracking side effects to assess safety and tolerability in adults with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–40
Countries
United States, Hungary, Romania, + 2 others
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.